c-Met

Product List

Creative Biolabs offers a wide range of high-quality products. To ensure the success of our clients' projects, we maintain a state-of-the-art R&D facility equipped with advanced tools and technologies. This allows us to offer advanced solutions and support to our clients, helping them to accelerate their research and bring innovative therapies to market. Please browse the following list to find the appropriate product for you.

Background

c-Met protein, also known as the hepatocyte growth factor receptor (HGFR), is a receptor tyrosine kinase that plays a crucial role in cell growth, proliferation, and survival. Aberrant activation or overexpression of c-Met has been observed in various types of cancers, including lung, breast, liver, and gastric cancer, and correlates with tumor progression, metastasis, and poor prognosis. Therefore, c-Met has emerged as a promising therapeutic target for cancer therapy.

Associated Diseases

T-cell lymphoblastic leukemia

Lung malignancy

Anti-c-Met CAR-T Services

Anti-c-Met CAR-T In Vitro Assays

Anti-c-Met CAR-T Expression Test

Creative Biolabs provides a comprehensive range of c-Met protein products for the direct measurement of CAR expression levels. In addition, we also offer customized anti-c-Met CAR-T expression tests. Our team of experts is committed to collaborating with clients to design and perform experiments tailored to their specific research needs.

Fig.1 The evaluation of anti-c-Met CAR expression.¹

Anti-c-Met CAR-T Proliferation Test

CAR-T cell proliferation assays include detecting the CAR-T cells labeling with a fluorescent dye by flow cytometry, cell counting, as well as the use of proliferation-related markers such as Ki-67 or PCNA. These techniques may have limitations and should be chosen based on the specific requirements of the study, such as sensitivity, throughput, and cost.

Fig.2 In vitro growth curves of anti-c-Met CAR-T cells.²

Anti-c-Met CAR-T Cytokine Release Test

Creative Biolabs provides Anti-c-Met CAR-T cytokine release tests that enable researchers to determine the ability of anti-c-Met CAR-T cells to produce and release cytokines in response to specific stimuli, which plays a vital role in understanding their immune-stimulating potential.

Fig.3 IL-2 release by anti-c-Met CAR-T cells with K562 or c-Met-K562 stimulation.¹

Anti-c-Met CAR-T In Vitro Cytotoxicity Assay

Our c-Met CAR-T cytotoxicity assays are important in determining the effectiveness of c-Met CAR-T cell therapies for cancer treatment.

Fig.4 The cell killing activity of anti-c-Met CAR-T against Met-positive tumor cells and SNU398 (Met negative) tumor cells.²

Anti-C-Met CAR-T In Vivo Assays

Anti-c-Met CAR-T Cell Therapy Animal Models

To evaluate the antitumor effects of CAR-T cells in vivo, At our lab, we offer a range of mouse tumor models, including xenograft, humanized, syngeneic, and transgenic models. These animal models play a crucial role in the development and evaluation of CAR-T therapies.

Efficacy Test of Anti-c-Met CAR-T

We perform comprehensive in vivo assays to thoroughly evaluate the therapeutic potential and safety of anti-c-Met CAR-T cells.

Fig.5 The antitumor activities of the anti-c-Met CAR-T cells. The anti-c-Met CAR-T cells specifically inhibited MHCC97H tumor growth.²

Toxicity Evaluation Anti-c-Met CAR-T

With our expert team and state-of-the-art technologies, we are committed to supporting the development of safe and effective CAR-T cell therapies for the treatment of various cancers and other diseases. We provide CAR-T toxicity study services to ensure the safety of CAR-T therapy.

Persistence of anti-c-Met CAR-T cell

CAR-T persistence is highly correlated with the life expectancy and survival of patients. To monitor the persistence of c-Met CAR-T cells in vivo, we evaluate CAR-T cell numbers over time by various techniques such as flow cytometry and BLI.

Fig.6 BLI imaging of anti-c-Met CAR-T cell expansion and persistence in vivo over time.²

References

1. Kang, Chung Hyo, et al. "C-Met-Specific chimeric antigen receptor T cells demonstrate anti-tumor effect in c-met positive gastric cancer." Cancers 13.22 (2021): 5738.
2. Qin, Anna, et al. "Tyrosine kinase signaling-independent MET-targeting with CAR-T cells." Journal of Translational Medicine 21.1 (2023): 682.